FDA ODE IV Director Feigal to join CBER as deputy director for medicine.
Executive Summary
FDA OFFICE OF DRUG EVALUATION IV DIRECTOR RECRUITMENT UNDER WAY to find a replacement for David Feigal, MD, who will be joining the Center for Biologics Evaluation & Research as deputy director for medicine effective Sept. 1. FDA will also have to step up its efforts to recruit a permanent director of the Division of Antiviral Drug Products: acting director Donna Freeman will be leaving the agency at the end of August.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: